169 related articles for article (PubMed ID: 15183125)
21. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
22. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
25. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
26. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
27. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
28. The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
Yuan HH; Han Y; Bian WX; Liu L; Bai YX
Pathology; 2012 Oct; 44(6):547-51. PubMed ID: 22935976
[TBL] [Abstract][Full Text] [Related]
29. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Andersson U; Johansson D; Behnam-Motlagh P; Johansson M; Malmer B
Acta Oncol; 2007; 46(7):951-60. PubMed ID: 17917826
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
31. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
32. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
33. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
Azzariti A; Porcelli L; Gatti G; Nicolin A; Paradiso A
Biochem Pharmacol; 2008 Mar; 75(5):1035-44. PubMed ID: 18191814
[TBL] [Abstract][Full Text] [Related]
34. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
36. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
[TBL] [Abstract][Full Text] [Related]
38. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
39. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
